Q2
COGT — Q2 2026 Financial Report Analysis
Cogent's Q2 2026 net loss widened 31% to $96.4M as launch-preparation costs more than doubled G&A, but $792M in cash and securities (plus $71M raised after quarter-end) funds it into late 2028, through FDA decisions on bezuclastinib due November 30 (GIST) and December 30 (NonAdvSM).